Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Diagnosis of Huntington's disease requires combination of clinical symptoms, radiological changes, genetic diagnosis

Diagnosis of Huntington's disease requires combination of clinical symptoms, radiological changes, genetic diagnosis

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

Thomson Reuters, Children's Tumor Foundation partner to create neurofibromatosis pathway maps

Thomson Reuters, Children's Tumor Foundation partner to create neurofibromatosis pathway maps

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Expert in gene therapy joins The Children's Hospital of Philadelphia

Expert in gene therapy joins The Children's Hospital of Philadelphia

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

New gene-editing system holds potential for treating many genetic disorders

New gene-editing system holds potential for treating many genetic disorders

Potassium boost improves walking, prolongs survival in mouse model of Huntington's disease

Potassium boost improves walking, prolongs survival in mouse model of Huntington's disease

Johns Hopkins neuroscientists identify cause of brain degeneration in Huntington's disease

Johns Hopkins neuroscientists identify cause of brain degeneration in Huntington's disease

FDA accepts Lundbeck's carbamazepine NDA for review

FDA accepts Lundbeck's carbamazepine NDA for review

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.